Theralase Technologies Inc. V.TLT

BTD alone won’t likely increase share price long term

[Dumbeldorfwhite]

Hoffmann et al. found no long-term excess returns of publicly listed companies developing a drug that recently received a breakthrough designation

https://link.springer.com/article/10.1007/s10198-023-01639-x#:~:text=Consequently%2C%20the%20price%20premium%20associated,a%20breakthrough%20designation%20%5B124%5D.

[DJDawg]

Thanks for sharing. I read those articles a while back and it had some interesting data. One thing that is, hopefully, different here is that TLT's has a unique technology an is positioned in a way that is not getting attention or respect. Many of the reasons for not getting respect are very legitimate given management history. The science part deserves the respect and most of us hope that

[Longholder99]

.....an OSC history in some investors opinions to be purposeful and undeserved, as a product of detractors trying to delay and or hamper the progress of a disruptor technology that will in all likelihood take a huge chunk out of Immuno drug profits.  IMO only of course.  

[Infinity]

BTD will certainly generate interest. I don't expect a huge jump in the SP.  Perhaps 0.40 to 0.50 range.  We all know TLT is grossly undervalued now and tax loss selling will put even more pressure to keep the price low.  In a recent interview RDW mentioned raising money via Non Dilutive investments.  It appears to me that he is already in talks for JV or some form of

[Infinity]

BTD will certainly generate interest. I don@t expect a huge jump in the SP.@ Perhaps 0.40 to 0.50 range.@ We all know TLT is grossly undervalued now and tax loss selling will put even more pressure to keep the price low.@ In a recent interview RDW mentioned raising money via Non Dilutive investments.@ It appears to me that he is already in talks for JV or some form of interest from a major pharma.